Clinical Trial Update: Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion [Phase 1]

View source ↗

Summary

This is a first-in-human Phase 1 study evaluating intravenous TKM-100201 for Ebola virus disease, focusing on safety, tolerability, and pharmacokinetics. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• TKM-100201

Snippet

Sponsor: Arbutus Biopharma Corporation | Conditions: Ebola Virus Infection | Phase 1 | Status: TERMINATED